Louis, E., Collard, A., Oger, A.F., Behaviour of Crohn's disease according to the Vienna classification: Changing pattern over the course of the disease (2001) Gut, 49, pp. 777-782
Solberg, I.C., Vatn, M.H., Høie, O., Clinical course in Crohn's disease: Results of a Norwegian population-based ten-year follow-up study (2007) Clin Gastroenterol Hepatol, 5, pp. 1430-1438
Jostins, L., Ripke, S., Weersma, R.K., Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease (2012) Nature, 491, pp. 119-124
Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial (2002) Lancet, 359, pp. 1541-1549
Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial (2007) Gastroenterology, 132, pp. 52-65
Sandborn, W.J., Feagan, B.G., Rutgeerts, P., Vedolizumab as induction and maintenance therapy for Crohn's disease (2013) N Engl J Med, 369, pp. 711-721
Sandborn, W.J., Gasink, C., Gao, L.L., Ustekinumab induction and maintenance therapy in refractory Crohn's disease (2012) N Engl J Med, 367, pp. 1519-1528
Monteleone, G., Neurath, M.F., Ardizzone, S., Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease (2015) N Engl J Med, 372, pp. 1104-1113
Colombel, J.F., Sandborn, W.J., Reinisch, W., Infliximab azathioprine or combination therapy for Crohn's disease (2010) N Engl J Med, 362, pp. 1383-1395
Uhlig, H.H., Schwerd, T., Koletzko, S., The diagnostic approach to monogenic very early onset inflammatory bowel disease (2014) Gastroenterology, 147, pp. 990-1007
Cosnes, J., Beaugerie, L., Carbonnel, F., Gendre, J.P., Smoking cessation and the course of Crohn's disease: An intervention study (2001) Gastroenterology, 120, pp. 1093-1099
Munkholm, P., Langholz, E., Davidsen, M., Binder, V., Disease activity courses in a regional cohort of Crohn's disease patients (1995) Scand J Gastroenterol, 30, pp. 699-706
Beaugerie, L., Brousse, N., Bouvier, A.M., Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study (2009) Lancet, 374, pp. 1617-1625
Louis, E., Irving, P., Beaugerie, L., Use of azathioprine in IBD: Modern aspects of an old drug (2014) Gut, 63, pp. 1695-1699
Van Der Valk, M.E., Mangen, M.J., Leenders, M., Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFa therapy: Results from the COIN study (2014) Gut, 63, pp. 72-79
Lémann, M., Mary, J.Y., Colombel, J.F., A randomized double-blind controlled withdrawal trial in Crohn's disease patients in long-Term remission on azathioprine (2005) Gastroenterology, 128, pp. 1812-1818
Van Assche, G., Magdelaine-Beuzelin, C., D'Haens, G., Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: A randomized trial (2008) Gastroenterology, 134, pp. 1861-1868
Sokol, H., Seksik, P., Carrat, F., Usefulness of co-Treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy (2010) Gut, 59, pp. 1363-1368
Reenaers, C., Louis, E., Belaiche, J., Does co-Treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? (2012) Aliment Pharmacol Ther, 36, pp. 1040-1048
Drobne, D., Bossuyt, P., Breynaert, C., Withdrawal of immunomodulators after co-Treatment does not reduce trough level of infliximab in patients with Crohn's disease (2015) Clin Gastroenterol Hepatol, 13, pp. 514-521
Louis, E., Mary, J.Y., Vernier-Massouille, G., Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped (2012) Gastroenterology, 142, pp. 63-70
Rutgeerts, P., Geboes, K., Vantrappen, G., Predictability of the postoperative course of Crohn's disease (1990) Gastroenterology, 99, pp. 956-963
